{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:07:21Z","timestamp":1790478441321,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T00:00:00Z","timestamp":1578700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Analysis"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jpha.2020.01.001","type":"journal-article","created":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T11:19:10Z","timestamp":1578741550000},"page":"517-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["The current status of anti-GPCR drugs against different cancers"],"prefix":"10.1016","volume":"10","author":[{"given":"Sana","family":"Usman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Khawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Rafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zara","family":"Naz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpha.2020.01.001_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tibtech.2004.12.006","article-title":"Structural genomics of GPCRs","volume":"23","author":"Lundstrom","year":"2005","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jpha.2020.01.001_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd3478","article-title":"Trends in the exploitation of novel drug targets","volume":"10","author":"Rask-Andersen","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpha.2020.01.001_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0092-8674(86)90785-3","article-title":"Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains","volume":"45","author":"Young","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.jpha.2020.01.001_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coph.2008.11.010","article-title":"Lysophosphatidic acid (LPA) and its receptors","volume":"9","author":"Noguchi","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jpha.2020.01.001_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fphar.2015.00048","article-title":"Peptide ligand recognition by G protein-coupled receptors","volume":"6","author":"Krumm","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jpha.2020.01.001_bib6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jpha.2020.01.001_bib7","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ijc.24383","article-title":"CXC-chemokine\/CXCR2 biological axis promotes angiogenesis in\u00a0vitro and in\u00a0vivo in pancreatic cancer","volume":"125","author":"Matsuo","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jpha.2020.01.001_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ijc.26035","article-title":"Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer","volume":"130","author":"Xu","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jpha.2020.01.001_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.semcancer.2013.08.009","article-title":"\u03b2-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy","volume":"23","author":"Tang","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jpha.2020.01.001_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1210\/er.2004-0017","article-title":"Gonadotropin-releasing hormone agonists in the treatment of prostate cancer","volume":"26","author":"Labrie","year":"2005","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jpha.2020.01.001_bib11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ejca.2009.11.004","article-title":"A\u00a0phase Ib\/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer","volume":"46","author":"Meyer","year":"2010","journal-title":"Eur. J. Cancer A"},{"key":"10.1016\/j.jpha.2020.01.001_bib12","author":"U S Food and Drug Administration"},{"key":"10.1016\/j.jpha.2020.01.001_bib13","first-page":"2599","article-title":"The G-protein coupled chemoattractant receptor FPR2 promotes malignant phenotype of human colon cancer cells","volume":"6","author":"Xiang","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.jpha.2020.01.001_bib14","first-page":"95","article-title":"Formyl peptide receptor 2 mediated chemotherapeutics drug resistance in colon cancer cells","volume":"22","author":"Su","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.jpha.2020.01.001_bib16","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.2174\/0929867324666170303121708","article-title":"Regulatory role of G protein-coupled receptors in pancreatic cancer development and progression","volume":"25","author":"Schuller","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jpha.2020.01.001_bib17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/pros.20738","article-title":"Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines","volume":"68","author":"Chow","year":"2008","journal-title":"The Prostate"},{"key":"10.1016\/j.jpha.2020.01.001_bib18","doi-asserted-by":"crossref","first-page":"12823","DOI":"10.18632\/oncotarget.7313","article-title":"G\u00a0protein-coupled receptor GPR160 is associated with apoptosis and cell cycle arrest of prostate cancer cells","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpha.2020.01.001_bib19","doi-asserted-by":"crossref","first-page":"29562","DOI":"10.1074\/jbc.M113.498436","article-title":"Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in\u00a0vivo","volume":"288","author":"Maussang","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jpha.2020.01.001_bib15","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1073\/pnas.0501535102","article-title":"G\u00a0protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the \u03b2-catenin pathway","volume":"102","author":"Yang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpha.2020.01.001_bib20","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.jpha.2020.01.001_bib21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/pros.20389","article-title":"The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase","volume":"66","author":"Wang","year":"2006","journal-title":"The Prostate"},{"key":"10.1016\/j.jpha.2020.01.001_bib22","doi-asserted-by":"crossref","first-page":"16218","DOI":"10.1074\/jbc.M109.012096","article-title":"Activation of an olfactory receptor inhibits proliferation of prostate cancer cells","volume":"284","author":"Neuhaus","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jpha.2020.01.001_bib23","first-page":"2235","article-title":"Evidence for a role of GPRC6A in prostate cancer metastasis based on case-control and in\u00a0vitro analyses","volume":"20","author":"Liu","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.jpha.2020.01.001_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13046-017-0561-x","article-title":"CRISPR\/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model","volume":"36","author":"Ye","year":"2017","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jpha.2020.01.001_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3747\/co.20.1672","article-title":"Provincial rates and time trends in pancreatic cancer outcomes","volume":"20","author":"Fung","year":"2013","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.jpha.2020.01.001_bib26","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1158\/0008-5472.CAN-09-0418","article-title":"Metformin disrupts crosstalk between G protein\u2013coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth","volume":"69","author":"Kisfalvi","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpha.2020.01.001_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.7150\/ijbs.14952","article-title":"The role of gastrin and CCK receptors in pancreatic cancer and other malignancies","volume":"12","author":"Smith","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jpha.2020.01.001_bib28","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jpha.2020.01.001_bib29","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaci.2014.01.037","article-title":"Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis","volume":"134","author":"Sic","year":"2014","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.jpha.2020.01.001_bib30","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1182\/blood-2004-07-2546","article-title":"Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells","volume":"105","author":"Runarsson","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jpha.2020.01.001_bib31","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.4049\/jimmunol.1102937","article-title":"Differential expression of neurotensin and specific receptors, NTSR1 and NTSR2, in normal and malignant human B lymphocytes","volume":"189","author":"Saada","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jpha.2020.01.001_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2362.1997.700623.x","article-title":"Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression","volume":"27","author":"Kamp","year":"1997","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.jpha.2020.01.001_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1365-2141.2003.04746.x","article-title":"Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cells","volume":"124","author":"Mamani-Matsuda","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jpha.2020.01.001_bib34","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1158\/1535-7163.MCT-13-0575-T","article-title":"PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2\/3) and CXCR4-mediated microenvironmental interactions (PIM1)","volume":"13","author":"Decker","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jpha.2020.01.001_bib35","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3324\/haematol.2009.013847","article-title":"The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces apoptosis, downregulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells","volume":"95","author":"Stamatopoulos","year":"2010","journal-title":"Haematol. Hematol. J."},{"key":"10.1016\/j.jpha.2020.01.001_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2141.2010.08316.x","article-title":"The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies","volume":"151","author":"Buchner","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jpha.2020.01.001_bib37","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2004-12-4918","article-title":"Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells","volume":"106","author":"Burger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jpha.2020.01.001_bib38","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1182\/blood-2008-06-165068","article-title":"Isoform-selective phosphoinositide 3\u2032-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell\u2013mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach","volume":"113","author":"Niedermeier","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jpha.2020.01.001_bib39","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1158\/0008-5472.CAN-15-0986","article-title":"Enhanced chemokine receptor recycling and impaired S1P1 expression promote leukemic cell infiltration of lymph nodes in chronic lymphocytic leukemia","volume":"75","author":"Patrussi","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpha.2020.01.001_bib40","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1\u2013transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jpha.2020.01.001_bib41","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14712598.2017.1347634","article-title":"Mogamulizumab for the treatment of T-cell lymphoma","volume":"17","author":"Makita","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jpha.2020.01.001_bib42","series-title":"World Cancer Report 2008","author":"Boyle","year":"2008"},{"key":"10.1016\/j.jpha.2020.01.001_bib43","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/cancers7020815","article-title":"Effects of age on the detection and management of breast cancer","volume":"7","author":"McGuire","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.jpha.2020.01.001_bib44","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.yexmp.2011.06.015","article-title":"G-protein coupled receptor-associated sorting protein 1 (GASP-1), a potential biomarker in breast cancer","volume":"91","author":"Tuszynski","year":"2011","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.jpha.2020.01.001_bib45","doi-asserted-by":"crossref","first-page":"13285","DOI":"10.1074\/jbc.M410922200","article-title":"Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40","volume":"280","author":"Hardy","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jpha.2020.01.001_bib46","first-page":"162","article-title":"ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches","volume":"1796","author":"Chen","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jpha.2020.01.001_bib47","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1073\/pnas.1320239111","article-title":"G-protein\u2013coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion","volume":"111","author":"Feigin","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jpha.2020.01.001_bib49","series-title":"World Cancer Report 2014","author":"McGuire","year":"2015"},{"key":"10.1016\/j.jpha.2020.01.001_bib50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1755-148X.2010.00781.x","article-title":"Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target","volume":"24","author":"Qin","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jpha.2020.01.001_bib51","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10585-010-9322-3","article-title":"GPR56 plays varying roles in endogenous cancer progression","volume":"27","author":"Xu","year":"2010","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.jpha.2020.01.001_bib52","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1158\/0008-5472.CAN-10-4543","article-title":"GPR56 Regulates VEGF production and angiogenesis during melanoma progression","volume":"71","author":"Yang","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpha.2020.01.001_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1877-1173(09)89001-7","article-title":"GPR56 and its related diseases","volume":"89","author":"Jin","year":"2009","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.jpha.2020.01.001_bib54","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1038\/onc.2012.278","article-title":"The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas","volume":"32","author":"P\u00e9rez-G\u00f3mez","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.jpha.2020.01.001_bib55","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1086\/319500","article-title":"Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair","volume":"68","author":"Bastiaens","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jpha.2020.01.001_bib56","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/hmg\/ddh043","article-title":"Interactive effects of MC1R and OCA2 on melanoma risk phenotypes","volume":"13","author":"Duffy","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jpha.2020.01.001_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008958","article-title":"The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans","volume":"5","author":"Loser","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jpha.2020.01.001_bib58","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/php.12335","article-title":"MC1R, eumelanin and pheomelanin: their role in determining the susceptibility to skin cancer, Photochem","volume":"91","author":"Nasti","year":"2015","journal-title":"Photobiol"}],"container-title":["Journal of Pharmaceutical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177919302874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177919302874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:31:20Z","timestamp":1761859880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095177919302874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2095177919302874"],"URL":"https:\/\/doi.org\/10.1016\/j.jpha.2020.01.001","relation":{},"ISSN":["2095-1779"],"issn-type":[{"value":"2095-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The current status of anti-GPCR drugs against different cancers","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpha.2020.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Xi'an Jiaotong University. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}